Land: Ierland
Taal: Engels
Bron: HPRA (Health Products Regulatory Authority)
Diclofenac sodium
PCO Manufacturing Ltd.
M02AA15
Diclofenac sodium
1 percent weight/weight
Gel
diclofenac
2019-03-22
_ _ _ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER VOLTAROL ® EMULGEL ® 1% W/W GEL diclofenac diethylammonium diclofenac diethylammonium 1.16% w/w corresponding to diclofenac sodium 1% w/w For joint, back and muscular pain relief Relieves pain, reduces inflammation, cooling effect READ ALL OF THIS LEAFLET CAREFULLY BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. This medicine is available without prescription. However, you still need to use Voltarol Emulgel 1% w/w Gel carefully to get the best results from it. − Keep this leaflet. You may need to read it again. Note that this leaflet is revised on a regular basis with the latest information on your medicine. Please refer to the date at the end of this leaflet. − Ask your pharmacist if you need more information or advice. − You must contact a doctor if your symptoms worsen or do not improve within 7 days. − If any of the side effects gets serious, or if you notice any side effect not listed in this leaflet, please tell your doctor or pharmacist. WHAT IS IN THIS LEAFLET 1. What Voltarol Emulgel 1% w/w Gel is and what it is used for 2. What you need to know before you use Voltarol Emulgel 1% w/w Gel 3. How to use Voltarol Emulgel 1% w/w Gel 4. Possible side effects 5. How to store Voltarol Emulgel 1% w/w Gel 6. Contents of the pack and other information 1. WHAT VOLTAROL EMULGEL 1% W/W GEL IS AND WHAT IT IS USED FOR Voltarol Emulgel 1% w/w Gel contains the active ingredient diclofenac which is from the group of medicines called non- steroidal anti-inflammatory drugs (NSAIDs). Voltarol Emulgel 1% w/w Gel is used in adults, the elderly and adolescents aged 14 years and over to relieve pain and reduce swelling in a number of painful conditions affecting the joints and muscles, e.g. sprains, strains and bruises. It is also used to relieve the pain of muscular rheumatism. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE VOLTAROL EMULGEL 1% W/W GEL DO NOT USE VOLTAROL EMULGEL 1% W/W GEL IF YOU: • are allergic (hypersensitive) to diclofenac, propylene glycol, benzy Lees het volledige document
Health Products Regulatory Authority 03 March 2022 CRN00CT0L Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Voltarol Emulgel 1% w/w Gel 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Contains: Voltarol Emulgel contains diclofenac diethylammonium 1.16% w/w corresponding to diclofenac sodium 1% w/w. Excipients with known effect: propylene glycol and benzyl benzoate For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Gel _Product imported from Germany_ Voltarol Emulgel is a white to slightly milky gel 4 CLINICAL PARTICULARS As per PA0678/140/002 5 PHARMACOLOGICAL PROPERTIES As per PA0678/140/002 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS diethylamine, Carbomer 974 P, cetomacrogol, cocoyl caprylocaprate, isopropyl alcohol, liquid paraffin, propylene glycol, purified water, perfume crème (containing benzyl benzoate) 6.2 INCOMPATIBILITIES Not applicable 6.3 SHELF LIFE The shelf-life expiry date of this product shall be the date shown on the tube and outer package of the product on the market in the country of origin. After first opening: 16 weeks. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 30 °C. Keep the tube in the outer carton in order to protect from light. Health Products Regulatory Authority 03 March 2022 CRN00CT0L Page 2 of 2 6.5 NATURE AND CONTENTS OF CONTAINER Sealed tubes closed with a screw cap incorporating a built-in point to pierce the seal before first use. Available in packs of 50 g and 100 g. Not all pack sizes may be marketed. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/442/001 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22 nd March 2019 10 DATE OF REVISION OF THE TEXT March 2022 Lees het volledige document